High Tolerability, Favorable Safety, and Subjects' Preference for a Single 200 mg/2 mL Tildrakizumab Injection: A Phase I, Open-Label, Randomized Crossover Trial in Healthy Volunteers.

Kokolakis, Georgios; Kreis, German; Falqués, Meritxell; Aparici, Mònica; Sondermann, Wiebke

High Tolerability, Favorable Safety, and Subjects' Preference for a Single 200 mg/2 mL Tildrakizumab Injection: A Phase I, Open-Label, Randomized Crossover Trial in Healthy Volunteers.

Kokolakis, Georgios; Kreis, German; Falqués, Meritxell; Aparici, Mònica; Sondermann, Wiebke.

Afiliación

Kokolakis G; Psoriasis Research and Treatment Center, Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. georgios.kokolakis@charite.de.
Kreis G; Almirall R&D, Sant Feliu de Llobregat, Barcelona, Spain.
Falqués M; Almirall R&D, Sant Feliu de Llobregat, Barcelona, Spain.
Aparici M; Almirall R&D, Sant Feliu de Llobregat, Barcelona, Spain.
Sondermann W; Department of Dermatology, Venereology and Allergology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Dermatol Ther (Heidelb) ; 12(9): 2135-2144, 2022 Sep.

Article en En | MEDLINE | ID: mdl-35984626

Palabras clave

Biologics; IL-23; Psoriasis; Tildrakizumab; Tolerability

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Dermatol Ther (Heidelb) Año: 2022 Tipo del documento: Article País de afiliación: Alemania

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google